COVID-19) study of inhaled Leukine
® (sargramostim, yeast-derived recombinant human GM-CSF) in hospitalized COVID-19 patients (NCT04326920).
1,2 This prospective, randomized, open-label study was led by University Hospital Ghent and conducted at five hospitals in Belgium. The study enrolled 81 patients with PCR-confirmed COVID-19 who were suffering from acute hypoxic respiratory failure requiring supplemental oxygen. The full study and translational results are being prepared for publication.
Lung dysfunction resulting in hypoxemia has been a hallmark of severe cases of COVID-19.
3,4,5 SARPAC was launched based on GM-CSF s role in restoring alveolar macrophages that have anti-inflammatory properties and serve to remove pathogens and other debris while maintaining alveolar surfactant.
SARPAC Clinical Trial of Leukine® (sargramostim, rhu GM-CSF) in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Scientists identify target to treat COVID pneumonia and reduce severity
Clinical trials with new experimental drug to begin early in 2021
Goal is to develop treatments that make COVID-19 no worse than a common cold
First comparison between immune mechanisms driving COVID-19 pneumonia with other pneumonias
CHICAGO - Bacteria or viruses like influenza that cause pneumonia can spread across large regions of the lung over the course of hours. In the modern intensive care unit, these bacteria or viruses are usually controlled either by antibiotics or by the body s immune system within the first few days of the illness.
But in a study published in
COVID-19 pneumonia causes more damage than typical pneumonia, says study ANI | Updated: Jan 12, 2021 23:19 IST
Washington [US], January 12 (ANI): Researchers from the Northwestern University claims that COVID-19pneumonia spreads like multiple wildfires, leaving destroyed lung tissue in its wake.
COVID pneumonia is significantly different from pneumonia caused by other causes, reports a new study. The infection leaves damage in its wake and fuels the fever, low blood pressure and damage to the kidneys, brain, heart and other organs in patients with COVID-19. Scientists discovered a target for treating COVID pneumonia.
Bacteria or viruses like influenza that cause pneumonia can spread across large regions of the lung over the course of hours. In the modern intensive care unit, these bacteria or viruses are usually controlled either by antibiotics or by the body s immune system within the first few days of the illness.